These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37758349)

  • 1. Response to Commentary on "Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-PD(L)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer".
    Chour A; Duruisseaux M
    J Thorac Oncol; 2023 Oct; 18(10):e114-e115. PubMed ID: 37758349
    [No Abstract]   [Full Text] [Related]  

  • 2. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS
    Chour A; Denis J; Mascaux C; Zysman M; Bigay-Game L; Swalduz A; Gounant V; Cortot A; Darrason M; Fallet V; Auclin E; Basse C; Tissot C; Decroisette C; Bombaron P; Giroux-Leprieur E; Odier L; Brosseau S; Creusot Q; Gueçamburu M; Meersseman C; Rochand A; Costantini A; Gaillard CM; Wasielewski E; Girard N; Cadranel J; Lafitte C; Lebossé F; Duruisseaux M
    J Thorac Oncol; 2023 Oct; 18(10):1408-1415. PubMed ID: 37217096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
    Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
    Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
    Ernst SM; Hofman MM; van der Horst TE; Paats MS; Heijboer FWJ; Aerts JGJV; Dumoulin DW; Cornelissen R; von der Thüsen JH; de Bruijn P; Hoop EO; Mathijssen RHJ; Koolen SLW; Dingemans AC
    EBioMedicine; 2024 Apr; 102():105074. PubMed ID: 38507877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.
    Desai A; Rakshit S; Bansal R; Ashara Y; Potter A; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Schwecke A; Moffett N; Hocum C; Leventakos K; Adjei A; Marks R; Molina J; Mansfield AS; Chen ZM; Dimou A
    Cancer Treat Res Commun; 2023; 36():100743. PubMed ID: 37531736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
    Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
    Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity.
    Kawamura T; Imamura CK; Kenmotsu H; Taira T; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mushiroda T; Takahashi T; Tanigawara Y
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):605-614. PubMed ID: 32040702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS
    Chiou LW; Chan CH; Jhuang YL; Yang CY; Jeng YM
    J Biomed Sci; 2023 Jun; 30(1):50. PubMed ID: 37386628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.
    Strohbehn GW; Sankar K; Qin A; Kalemkerian GP
    Expert Opin Pharmacother; 2022 Oct; 23(14):1569-1575. PubMed ID: 36217844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Sotorasib on the Pharmacokinetics and Pharmacodynamics of Metformin, a MATE1/2K Substrate, in Healthy Subjects.
    Vuu I; Wahlstrom J; Houk BE
    Clin Pharmacokinet; 2023 Feb; 62(2):267-275. PubMed ID: 36529835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a simple high-performance liquid chromatography-ultraviolet method for sotorasib quantification in human plasma: Implications for therapeutic drug monitoring.
    Hikita E; Gando Y; Chubachi H; Shirota M; Kushiyama A; Yasu T
    Drug Discov Ther; 2023 Sep; 17(4):289-293. PubMed ID: 37599084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients.
    Xin S; Fang W; Li J; Li D; Wang C; Huang Q; Huang M; Zhuang W; Wang X; Chen L
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):725-737. PubMed ID: 33387041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
    Hoshiyama H
    Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe Immune Checkpoint Inhibitor Hepatitis in
    Begum P; Goldin RD; Possamai LA; Popat S
    JTO Clin Res Rep; 2021 Sep; 2(9):100213. PubMed ID: 34590053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].
    Bessy C; Blin T; Pichon E; Marchand-Adam S; Carmier D
    Rev Mal Respir; 2023 Jan; 40(1):17-23. PubMed ID: 36566134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of an LC-MS/MS method for the determination of sotorasib, a KRAS
    Wong P; Akrami A; Houk B; Vuu I; James CA
    Bioanalysis; 2022 Oct; 14(19):1281-1292. PubMed ID: 36473022
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.